MET and non-small cell lung carcinoma: Increasing evidence suggests that tumors harboring such mutations are sensitive to MET inhibition, and a number of selective MET tyrosine kinase inhibitors have demonstrated clinical activity in patients with METex14 skipping NSCLC [2].